RAFA To Add Major Component to the Tashkent Pharma Park
RAFA To Add Major Component to the Tashkent Pharma Park
Nicosia, Cyprus, Dec. 17, 2021 (GLOBE NEWSWIRE) -- Rafarma Pharmaceuticals, Inc. OTC:(RAFA) and the Czech company "Block" signed an agreement on the implementation of the construction of a scientific and pharmaceutical complex in the territory of the Tashkent Pharma Park in Uzbekistan. The new partner of the promising project is the multinational engineering group BLOCK with a unique specialization and experience in the field of healthcare and pharmacology. The interests of Rafarma in this agreement will be represented by the company RAFA Therapeutics Uzbekistan.
塞浦路斯尼科西亚,2021年12月17日(环球通讯社)拉法玛制药公司场外交易:(RAFA)与捷克“Block”公司签署了在乌兹别克斯坦塔什干医药园区境内建设科学和医药综合体的实施协议。这个前景看好的项目的新合作伙伴是在医疗保健和药理学领域拥有独特专业化和经验的跨国工程集团Block。Rafarma在这项协议中的利益将由乌兹别克斯坦Rafa治疗公司代表。
In accordance with the agreement, Block will undertake the design of the future complex, including a system of clean laboratory rooms with all the necessary equipment within the framework of the project. The centerpiece will be a project for a plant to produce drugs from human blood plasma with a potential processing capacity of more than 1 million liters of plasma per year and an investment volume of more than US $50 million dollars. Its launch will allow Uzbekistan to become one of the 10 countries in the world with the largest fractionation plants for the processing of blood components.
根据协议,布洛克将承担未来综合体的设计,包括一个干净的实验室系统,以及项目框架内所有必要的设备。该项目的核心将是一个从人体血浆中生产药物的工厂项目,该项目的潜在处理能力为每年100多万升血浆,投资额超过5000万美元。它的推出将使乌兹别克斯坦成为世界上拥有最大的血液成分分馏工厂的10个国家之一。
We plan to complete the design work in April 2022 and begin construction of the first phase of the plant in the summer of 2022.
我们计划在2022年4月完成设计工作,并在2022年夏天开始建设一期工厂。
This latest development is part of Rafarma Pharmaceuticals' previous announcement to build a scientific and pharmaceutical complex in the territory of the Tashkent Pharma Park by the end of 2026. At the first stage, it is planned to organize the production of cancer drugs and drugs from human donor blood plasma. At the second stage, a complex will be built for the production of drugs based on antibodies (-MABs) and radiopharmaceuticals used for the diagnosis and treatment of various types of cancer. In addition to modern high-tech production lines, the project provides for the creation of a network of laboratories for the collection of blood plasma, the total investment is US $85 million dollars. Experts recognize these construction plans as the largest innovative project of the industrial zone of the Tashkent Pharma Park pharmaceutical cluster.
这一最新进展是拉法玛制药公司此前宣布的在2026年底之前在塔什干制药园区境内建造一个科学和制药综合体的一部分。在第一阶段,计划组织从人类捐赠者血浆中生产抗癌药物和药物。在第二阶段,将建造一个综合体,用于生产基于抗体(-MAbs)和用于诊断和治疗各种癌症的放射性药物的药物。除了现代化的高科技生产线外,该项目还将建立一个血浆采集实验室网络,总投资为8500万美元。专家认为,这些建设计划是塔什干医药园区医药集群工业区最大的创新项目。
Forward-Looking Statements: This press release contains "forward-looking statements" within the meaning of Section 21E of the Securities Exchange Act of 1934. Except for historical matters contained herein, statements made in this press release are forward-looking statements. Without limiting the generality of the foregoing, words such as "may", "will", "to", "plan", "expect", "believe", "anticipate", "intend", "could", "would", "estimate," or "continue", or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements. Forward-looking statements involve known and unknown risk, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Also, forward-looking statements represent our management's beliefs and assumptions only as of the date hereof. Additional information regarding the factors that may cause actual results to differ materially from these forward-looking statements is available in the Company's filings with OTC Markets. Except as required by law, we assume no obligation to update these forward-looking statements publicly or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.
前瞻性陈述:本新闻稿包含1934年证券交易法第21E节所指的“前瞻性陈述”。除本文包含的历史事项外,本新闻稿中的陈述均为前瞻性陈述。在不限制前述一般性的情况下,诸如“可能”、“将”、“到”、“计划”、“预期”、“相信”、“预期”、“打算”、“可能”、“将”、“估计”或“继续”等词语或其负面的其他变体或类似术语旨在识别前瞻性陈述。前瞻性陈述涉及已知和未知的风险、不确定因素和其他因素,这些风险、不确定性和其他因素可能导致我们的实际结果、表现或成就与前瞻性陈述明示或暗示的任何未来结果、表现或成就大不相同。此外,前瞻性陈述仅代表我们管理层截至本文发布之日的信念和假设。有关可能导致实际结果与这些前瞻性陈述大不相同的因素的更多信息,请参阅公司向场外交易市场提交的文件。除非法律要求,否则我们没有义务公开更新这些前瞻性陈述,或更新实际结果可能与这些前瞻性陈述中预期的结果大不相同的原因,即使未来有新的信息。
For more information contact:
RAFARMA
(307) 429-2029
如需更多信息,请联系:
拉法尔马
(307) 429-2029